TTrialPathMatch Me to Trials
← Back to trials
RecruitingChronic Liver Disease (CLD)Liver Fibrosis

Correlation Of EUS-SWQ And Liver Fibrosis Pathology In Chronic Liver Disease

Eligible age

18–80 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this clinical study is to learn whether the Olympus EU-ME3 endoscopic ultrasound shear wave quantification (EUS-SWQ) function can accurately diagnose and grade liver fibrosis in patients with chronic liver disease. It will also learn about the safety and measurement success rate of EUS-SWQ. The main questions it aims to answer are: How closely do EUS-SWQ measurements match liver fibrosis stages determined by liver biopsy (the reference standard)? Does EUS-SWQ correlate better with liver biopsy results than FibroScan? How safe is EUS-SWQ and how often can successful measurements be obtained? Researchers will compare EUS-SWQ results with liver biopsy pathology (METAVIR F0-F4) and with FibroScan results to evaluate its diagnostic value. Participants will: Be adults with chronic liver disease who are scheduled to undergo a clinically indicated liver biopsy Undergo an EUS-SWQ examination as part of the study Have their liver stiffness measured by both EUS-SWQ and FibroScan for comparison Be monitored for any discomfort or adverse events related to the procedures A total of 65 participants will take part in this prospective, single-center, post-market clinical study.

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

You may qualify if…

  • ✓ 1. Age ≥ 18 years and ≤ 80 years.
  • ✓ 2. Patients with clinical indications scheduled to undergo liver biopsy (EUS-guided) for the evaluation of liver lesions. Chronic liver disease meeting criteria for biopsy includes:Hepatitis B;Fatty liver disease;Autoimmune hepatitis;Other chronic liver diseases of unknown etiology that would benefit from liver biopsy
  • ✓ 3. Planned to undergo EUS-SWQ and FibroScan examinations prior to biopsy.
  • ✓ 4. Willing to provide and sign written informed consent.

You may not qualify if…

  • ✕ 1. Patients unable to tolerate endoscopic procedures.
  • ✕ 2. Patients with contraindications to endoscopy or anesthesia.
  • ✕ 3. Coagulopathy (platelet count \< 50×10⁹/L, PT \> upper limit of normal by 3 seconds).
  • ✕ 4. Patients with severe underlying diseases of the respiratory, cardiovascular, cerebrovascular, digestive, or hematologic systems, as well as those with psychiatric disorders.
  • ✕ 5. Patients with surgically altered anatomy that precludes adequate EUS imaging of the hepatic parenchyma.
  • ✕ 6. Patients with imaging findings suggestive of malignant liver tumors.
  • ✕ 7. Pregnant or lactating women.
  • ✕ 8. Patients with decompensated cirrhosis (gastrointestinal bleeding, ascites, encephalopathy).

Source: ClinicalTrials.gov · NCT07588854 · last updated 2026-05-15

Correlation Of EUS-SWQ And Liver Fibrosis Pathology In Chronic Liver D · TrialPath